Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VEDOLIZUMAB
- Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
- A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
- A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
- Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
- Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
- A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- LFMT vs Placebo in New Biologic Start for Ulcerative Colitis
- Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
- Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
- Targeted Fluorescence Imaging in AMD
- Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
- Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
- Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease
- A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
- Vedolizumab for Immune Mediated Colitis
- A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease
- A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis
- A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
- Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
- NIR FME of Labelled Vedolizumab to Elucidate the Mechanism of Action and Predicting Response in IBD Patients.
- Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
- A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
- A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants
- A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
- A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
- EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis
- Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
- Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
- Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Impact of Fecal Microbiota Transplantation in Ulcerative Colitis
- A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
- Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.
- An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
- Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease
- Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
- Autologous Stem Cell Transplant for Crohn's Disease
- Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- Defining Predictors of RT Response to Vedolizumab in IBD
- Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
- A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
- An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection
- Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
- Synergistic Effect of Vedolizumab and Pentoxifylline
- Vedolizumab Induction May Prevent Celiac Enteritis
- Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
- Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
- Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
- Vedolizumab Post Op Study
- Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
- A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
- Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
- Triple Combination Therapy in High Risk Crohn's Disease (CD)
- Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
- Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
- Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.
- Clinical and Molecular Phenotyping in IBD
- OTIS Vedolizumab Pregnancy Exposure Registry
- Entyvio (Vedolizumab) Long Term Safety Study
- A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study
- An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis
- Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
- A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
- Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
- Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
- Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
- An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
- Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
- Corticosteroids With Vedolizumab in Crohn's Disease
- Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
- Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
- Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
- Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
- Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
- Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
- An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
- Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
Clinical trials list
click for details